Nobody keeps an official list of cannabis companies worth buying. The large U.S. multi-state operators that keep coming up are Green Thumb Industries, Curaleaf, Trulieve, Verano, and Cresco Labs. On the Canadian side, Tilray Brands and Canopy Growth trade on major U.S. exchanges. Start with those filings this week.
Check whether an operator is licensed, can meet near-term obligations from public filings, and is operating under federal tax and capital-market constraints. Use that filter to decide what to read.
If you already follow cannabis business news, start with public filings rather than brand familiarity. Read the latest quarterly report or management discussion before you consider a share. Cannabis remains federally prohibited in the United States. Internal Revenue Code Section 280E and limited access to ordinary banking still constrain much of the industry. That mix is why a familiar operator can look inexpensive on a screen and still sit poorly in an individual account.
If a ticker is on your radar, pull the most recent quarterly filing. Compare cash with near-term debt. Confirm the states where that operator actually holds licenses. Consumer brand loyalty does not transfer to the stock.
How do you tell a cannabis company is worth a closer look?
Start with licenses, cash, near-term obligations, and dilution. If you cannot answer those four from public filings, you do not have a thesis yet.
A U.S. operator’s business depends on the state licenses it holds. State cannabis regulators issue those licenses, can limit how many exist, and can make them hard to replace. Read the business section of the latest quarterly or annual report and note the states claimed. Then check each state’s cannabis control board site to see whether the company, or a named subsidiary, still appears.
Cash matters because many cannabis firms still cannot use ordinary bank credit the way a typical retailer can. Look at cash on the balance sheet, then look at debt coming due and operating cash flow in the same filing. Ask whether the company can fund itself without another equity raise.
Section 280E of the Internal Revenue Code disallows ordinary business deductions for businesses trafficking in federally controlled substances. A cannabis retailer can report sales and still show a heavy tax line. Skip the full financial model and read the tax discussion in the filing.
Dilution can reduce existing shareholders’ ownership if the share count rises to fund operations. The share-capital note in the filing is the place to look.
If you pick one ticker, do only that work: licenses, cash, 280E language, and share count.
Which public cannabis companies do investors watch?
The same names keep showing up in coverage: Green Thumb Industries, Curaleaf, Trulieve, Verano Holdings, and Cresco Labs on the U.S. multi-state side, plus Tilray Brands and Canopy Growth among Canadian producers you can find in a standard U.S. brokerage search.
Coverage follows those names because they are familiar and their documents are public. Tilray and Canopy list on major U.S. exchanges, while many U.S. multi-state operators trade over the counter.
If you spend time on filings, start with those names because the documents are public and easy to find. If you only open two documents, open the latest quarterly report for one U.S. multi-state operator and one Canadian licensed producer and read the liquidity language side by side. Capital structures can differ.
What should you check before you buy anything?
Open the SEC’s EDGAR database for U.S. filers, or SEDAR+ for Canadian ones, and download the latest quarterly report. Then open the state cannabis regulator’s public license search for every state that company claims.
Confirm your brokerage will let you buy the ticker. Many U.S. cannabis operators trade over the counter, and some firms restrict those names. A Nasdaq-listed ticker can be easier to buy than an OTC name.
Read the risk factors. In this industry they often describe federal enforcement risk, Section 280E, possible state license loss, and limited capital access.
Decide what you can afford to lose. Public cannabis equity has been difficult for many holders over long stretches, and nothing in this article predicts a turnaround or a promised return.
The legal landscape for cannabis, and for securities tied to cannabis, keeps changing. Confirm your own local laws, tax rules, and brokerage policies before you act on anything here. This is not investment, tax, or legal advice.
Frequently asked questions
Can I legally buy cannabis stocks in the US?
In most cases yes, through a brokerage, even though cannabis remains illegal under federal law. Some brokers restrict OTC cannabis names. Confirm with your firm before you try to place an order.
Why not just pick the brand I already buy?
A product you like tells you almost nothing about cash, debt, licenses, or dilution. Read the latest quarterly filing and the state license list before you treat a brand as a stock.
Are Canadian cannabis stocks safer than US ones?
They often list on larger exchanges, which can mean easier access. They still face weak demand, capital needs, and policy risk. Do not treat a Nasdaq ticker as a quality stamp.
What is 280E and why does it matter for investors?
Section 280E of the Internal Revenue Code blocks normal business deductions for federally illegal controlled substances. U.S. operators can show sales and still have little room after tax. Read the tax note in the filing.
Should I wait for federal reform before I invest?
You can wait. You can also read filings now. Policy talk moves faster than law. Do not buy a stock because a hearing sounded friendly.
